Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus ankara-boosted swedish vaccinees

AIDS Research and Human Retroviruses

Volumn 30, Issue 3, 2014, Pages 299-311

  Nilsson, Charlotta ^a,b   Godoy Ramirez, Karina ^a   Hejdeman, Bo ^b   Bråve, Andreas ^a,b   Gudmundsdotter, Lindvi ^a,b,f   Hallengärd, David ^a,b   Currier, Jeffrey R ^c   Wieczorek, Lindsay ^c   Hasselrot, Klara ^d   Earl, Patricia L ^e   Polonis, Victoria R ^c   Marovich, Mary A ^c,e   Robb, Merlin L ^c   Sandström, Eric ^b   Wahren, Britta ^a,b   Biberfeld, Gunnel ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Affibody AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 140; HIV MODIFIED VACCINIA VIRUS ANKARA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SWEDEN; VACCINATION;

AIDS VACCINES; CELL PROLIFERATION; CYTOKINES; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; MALE; SWEDEN; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84895540725     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0149     Document Type: Article

References (35)

1. UNAIDS: 2012 UNAIDS report on the global AIDS epidemic. www.unaids.org/en/media/unaids/content assets/documents/epidemiology/2012/ gr2012/20121120-UNAIDS-Global-Report-2012-with-annexes-en.pdf.
2. Girard MP, Osmanov S, Assossou OM, and Kieny M-P: Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 2011;29: 6191-6218.
3. Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, et al.: Prevention of infection by granulocyte macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011;204:164-173.
4. Letvin NL, Rao SS, Montefiori D, Seaman MS, Sun Y, Lim S-Y, et al.: Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011;3:81ra36.
5. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482:89-93.
6. + T-cellmediated control of HIV and SIV infection. Immunol Res 2011;49:135-146.
7. Soghoidan DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al.: HIV-specific cytolytic CD4 T cell responses during acute infection predict disease outcome. Sci Trans Med 2012;4:123ra25.
8. Kim JH, Rerks-Ngarm S, Excler J-L, and Michael NL: HIV vaccines: Lessons learned and the way forward. Curr Opin HIV AIDS 2010;5:428-434.
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med 2009;362:2209-2220.
10. Haynes BF, Gilbert PB, McElrath JM, Zolla-Pazner S, Tomaras GD, Alam M, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Eng J Med 2012;366:1275-1286.
11. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al.: The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188:5166-5176.
12. Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, et al.: Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008;198:1482-1490.
13. + and CD8+ Tlymphocytes proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus Ankara expressing HIV-1 genes. Clin Vaccine Immunol 2010;17:1124-1131.
14. Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, et al.: Design and evaluation of multi-gene, multi-clade HIV- 1 MVA vaccines. Vaccine 2009;27:5885-5895.
15. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al.: Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011;28: 8417-8428.
16. Gudmundsdotter L, Nilsson C, Bråve A, Hejdeman B, Earl P, Moss B, et al.: Recombinant modified vaccinia Ankara (MVA) efficiently boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009;27:4468-4474.
17. Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, et al.: A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1 specific CD8 + T cells and humoral responses in mice. Mol Ther 2007;15:1724-1733.
18. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, et al.: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71:5069-5079.
19. Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Curr Protocall Immunol 2004;Chapter 12, unit 11 (12.11.1-12.11.17).
20. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, et al.: Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010;408:1-13.
21. Hasselrot K, Bratt G, Hirbod T, Säberg P, Ehnlund M, Lopalco L, et al.: Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. AIDS 2010;24:35-43.
22. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, et al.: Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia-Ankara-HIV-1 vaccine candidate. PLoS One 2010:5:e13983.
23. Harari A, Bart P-A, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al.: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and longlasting T cell responses. J Exp Med 2008;205:63-77.
24. Hanke T, Goonetilleke N, McMichael AJ, and Dorrell L: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007;88:1-12.
25. Gorse GJ, Newman MJ, deCamp A, Hay CM, De Rosa SC, Noonan E, et al.: DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper-T lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naïve adults. Clin Vaccine Immunol 2012;5:649-658.
26. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al.: A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011;8:e21225.
27. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, et al.: Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5:e9015.
28. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al.: A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east Africans. J Infect Dis 2010;201:600-607.
29. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al.: Safety and immunogenicity study of multiclade HIV-1 adenovirus vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine alone. PLoS One 2010;5:e12873.
30. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, et al.: Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized clinical trial. PLoS One 2011;6:e24517.
31. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al.: Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2010;203:610-619.
32. Elrath MJ: Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J Infect Dis 2010;202(Suppl2):S323-326.
33. Zhao J, Lai L, Amara RR, Montefiori DC, Villinger F, Chennareddi L, et al.: Preclinical studies of human immunodeficiency virus/AIDS vaccines: Inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009;83:4102-4111.
34. Mehendale S, Thankar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, et al.: Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: A phase I randomized trial in HIV-uninfected Indian volunteers. PLoS One 2013;8:e55831.
35. Brown BK, Wieczorek L, Jijak G, Lombardi K, Currier J, Wesberry M, et al.: The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS One 2012;7:e29454.